TFRC and neoplasm: Theoretically, upon entry into the bloodstream, DSNClew, guided by aptamers, targets tumor cells overexpressing nucleolin and transferrin receptors on their surfaces, enters cells via endocytosis, and releases siRNA, which binds to the RNA-induced silencing complex in the cytoplasm.